Other drug manufacturers declined in the days following the nomination. Pfizer and Moderna have declined 6.9% and 6.2% ...

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

According to The People’s Vaccine Alliance, Comirnaty costs an estimated $1.18 per dose to produce. For over two years now, the US government has been running its public vaccination campaign ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Revenue came in at $17.7 billion, an increase of 31% year over year, which is beyond excellent for a pharmaceutical giant.

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...